FDA Panel Says Data Do Not Support Lower Cardiac Risk of Naproxen

According to the FDA's Arthritis Advisory Committee, available evidence does not prove that the nonsteroidal anti-inflammatory drug naproxen - mainly marketed in the U.S. as Aleve and as generic store brand formulations - has a lower cardiac risk than rival products.

http://ift.tt/1jcNq90